Alpha-Synuclein Aggregation Breakers

Alpha-Synuclein Aggregation Breakers

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Alpha-Synuclein Aggregation Breakers</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Original Indication</td>
</tr>
<tr>
<td class="label">Dicyclomine</td>
<td>Antispasmodic</td>
</tr>
<tr>
<td class="label">Cromolyn</td>
<td>Mast cell stabilizer</td>
</tr>
<tr>
<td class="label">Rifampicin</td>
<td>Antibiotic</td>
</tr>
<tr>
<td class="label">Tetracycline</td>
<td>Antibiotic</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">Anle138b</td>
<td>Anle138b</td>
</tr>
<tr>
<td class="label">Small molecule X</td>
<td>Novel</td>
</tr>
</table>

Alpha-synuclein aggregation breakers are small molecules that specifically prevent or reverse the pathological aggregation of alpha-synuclein (α-syn) into toxic oligomers and fibrils. Unlike general aggregation inhibitors or immunotherapies, aggregation breakers are designed to bind directly to the NACore (non-Aβ component, residues 61-95) and prevent the conformational transition from monomeric α-syn to β-sheet-rich structures. [@Pujols2018]

Rationale for Aggregation Breakers

The pathological cascade in synucleinopathies involves: [@wandt2021]

Alpha-Synuclein Aggregation Breakers

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Alpha-Synuclein Aggregation Breakers</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Original Indication</td>
</tr>
<tr>
<td class="label">Dicyclomine</td>
<td>Antispasmodic</td>
</tr>
<tr>
<td class="label">Cromolyn</td>
<td>Mast cell stabilizer</td>
</tr>
<tr>
<td class="label">Rifampicin</td>
<td>Antibiotic</td>
</tr>
<tr>
<td class="label">Tetracycline</td>
<td>Antibiotic</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">Anle138b</td>
<td>Anle138b</td>
</tr>
<tr>
<td class="label">Small molecule X</td>
<td>Novel</td>
</tr>
</table>

Alpha-synuclein aggregation breakers are small molecules that specifically prevent or reverse the pathological aggregation of alpha-synuclein (α-syn) into toxic oligomers and fibrils. Unlike general aggregation inhibitors or immunotherapies, aggregation breakers are designed to bind directly to the NACore (non-Aβ component, residues 61-95) and prevent the conformational transition from monomeric α-syn to β-sheet-rich structures. [@Pujols2018]

Rationale for Aggregation Breakers

The pathological cascade in synucleinopathies involves: [@wandt2021]

Aggregation breakers target the earliest stages of this cascade—preventing the initial nucleation and blocking the growth of existing aggregates. This approach differs from: [@devine2021]

• Immunotherapies: Target extracellular aggregates for clearance
• Gene therapy/ASOs: Reduce α-syn expression levels
• Autophagy enhancers: Promote aggregate clearance post-formation

Mechanism of Action

Direct Binding to NACore

The NACore (residues 61-95) is the central aggregation-prone domain of α-syn. Aggregation breakers typically: [@Bharate2022]

• Bind hydrophobic residues within NACore (Val70, Phe94, Ala78)
• Block inter-molecular β-sheet formation
• Stabilize monomeric or off-pathway conformations
• Prevent seeding of further aggregation

Thermodynamic Stabilization

Small molecule binding increases the thermal stability of monomeric α-syn, shifting the equilibrium away from aggregation-prone states: [@horvath2022]

Inhibition of Secondary Nucleation

Advanced aggregation breakers can: [@lorenz2023]

• Block the templating effect of existing fibrils
• Prevent fragmentation that creates new seed nuclei
• Dissociate pre-formed oligomers

Clinical Candidates

Anle138b

Mechanism: Binds to NACore (Val70, Phe94 binding pocket), inhibits oligomer and fibril formation. [@Levin2019]

• Company: MODAG (acquired by/licensed to Teva)
• Development Status: Phase 1 completed in 2020
• Clinical Trial: NCT04449486 (completed)
• Key Findings:
• Safe and well-tolerated in healthy volunteers
• Dose-dependent PK with brain penetration
• Target engagement demonstrated in CSF biomarkers
• Preclinical Data: Rescued motor deficits in α-syn transgenic mice, reduced oligomer levels

SynuClean-D

Mechanism: Dual inhibitor identified through high-throughput screening—blocks both primary nucleation and secondary nucleation. [@carbajal2023]

• Development Status: Preclinical/IND-enabling
• Company: Araclon Biotech / spinning out
• Key Findings:
• IC50 ~0.8 μM for fibrillation
• Rescues neuronal viability in cellular models
• Reduces α-syn toxicity in C. elegans and mouse models

EGCG (Epigallocatechin Gallate)

Mechanism: Polyphenol that binds to α-syn, prevents fibril formation through multiple mechanisms. [@mohan2021]

• Source: Green tea extract
• Development Status: Several small clinical trials
• Key Findings:
• Modest improvement in PD symptoms in some trials
• Bioavailability challenges
• Good safety profile

Curcumin and Analogs

Mechanism: Binds to NACore, inhibits β-sheet formation, antioxidant properties. [@srivastava2020]

• Development Status: Preclinical/early clinical
• Key Findings:
• Fluorescent properties useful for monitoring binding
• Analogs with improved BBB penetration in development

UBL-0401 (Ublituximab-based)

Mechanism: Targets α-syn aggregation through novel mechanism

• Company: Lundbeck
• Development Status: Phase 1/2

Small Molecule Library Screens

Multiple drug repurposing screens have identified candidates: [@demartini2023]

Preclinical Candidates

Peptide-Based Breakers

• Designed peptides mimicking NACore sequence
• Modified to improve stability and BBB penetration
• Some showing promise in animal models

Metal Chelators

• Cu/Zn chelators reduce metal-induced aggregation
• PBT2 (Prana Biotechnology) reached Phase 2

Natural Products

• Resveratrol: Sirt1 activation + aggregation inhibition
• Quercetin: Flavonoid with anti-aggregation activity
• Ginsenosides: Panax ginseng components

Clinical Trial Landscape

Active and Recent Trials

Failed Programs

• Cromolyn: Phase 1 failed to show efficacy
• Rifampicin: Mixed results in PD trials
• Biogen BIIB054 (Cinpanemab): Phase 2 failed (antibody, not small molecule)

Biomarkers for Target Engagement

• CSF α-syn oligomers: Decreased with effective target engagement
• α-syn RT-QuIC: Seed amplification to detect aggregation
• pSer129 α-syn: Pathological form in CSF
• Neurofilament light chain (NfL): Marker of neurodegeneration

Challenges and Limitations

Combination Strategies

Aggregation breakers may combine with: [@devine2021]

• Immunotherapies: Sequential or concurrent treatment
• Autophagy enhancers: Clear existing aggregates
• Gene therapy: Long-term α-syn reduction
• Neuroprotective agents: Address oxidative stress, mitochondrial dysfunction

Cross-References

• [Alpha-synuclein](/proteins/alpha-synuclein) - Protein page
• [Alpha-synuclein aggregation pathway](/mechanisms/alpha-synuclein-aggregation-pathway)
• [Alpha-synuclein aggregation inhibitors](/therapeutics/alpha-synuclein-aggregation-inhibitors)
• [Alpha-synuclein immunotherapy](/therapeutics/alpha-synuclein-immunotherapies)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies)
• [Multiple System Atrophy](/diseases/multiple-system-atrophy)
• [α-synuclein prion-like spreading](/mechanisms/alpha-synuclein-prion-like-spreading)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding](/hypothesis/h-8b7727c1) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: CSGA
• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [Gut Barrier Permeability-α-Synuclein Axis Modulation](/hypothesis/h-6c83282d) — <span style="color:#ffd54f;font-weight:600">0.60</span> · Target: CLDN1, OCLN, ZO1, MLCK
• [Microbial Metabolite-Mediated α-Synuclein Disaggregation](/hypothesis/h-74777459) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: SNCA, HSPA1A, DNMT1

Related Analyses:

• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;
• [Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e) &#x1f504;